CDA | Evidence Driven
CDA | Evidence Driven

Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1341-000

Question

  1. What is the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in rural and remote settings?

Key Message

There is a lack of evidence on the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in rural and remote settings. In remote Indigenous communities with known history of bacillus Calmette-Guérin vaccination, more positive tests results were reported with the tuberculin skin test than with the interferon gamma release assay.

Files

Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings Rapid Response April 7, 2021 View PDF

Related Content

Last Updated : April 9, 2021